Pregnancy with type 1 diabetes requires careful attention—but today it can be managed far more safely and predictably than it could only a few years ago. Modern insulins, continuous glucose monitoring (CGM), and automated insulin delivery (AID) systems have substantially improved the conditions for achieving good glucose control throughout pregnancy.
Good glucose control reduces the risk of complications for both mother and baby. However, an equally important message is this: even with excellent diabetes management, occasional high or low glucose values cannot be completely avoided. Such fluctuations are part of living with type 1 diabetes and should not be regarded as personal failure.
The goal is therefore not a “perfect” individual glucose reading. What matters is the overall pattern: How often, how high or low, and for how long are glucose levels outside the target range? Are the same patterns occurring repeatedly?
This distinction is particularly important because a CGM system generates thousands of glucose readings every week. Interpreting every single elevated value as a danger to the baby can create enormous and unnecessary anxiety—and does not reflect the way modern diabetes management evaluates glucose control.
Ideally, pregnancy should be planned. Glucose levels should be as close to normal as safely possible before conception, while avoiding frequent or severe hypoglycemia.
A preconception HbA1c below 6.5% (48 mmol/mol) is recommended if this can be achieved without problematic hypoglycemia.
The period around conception is particularly important because the baby’s organs begin developing during the first weeks of pregnancy. A substantially elevated HbA1c during this period is associated with an increased risk of congenital malformations and miscarriage.
Preconception assessment should also include:
ACE inhibitors and angiotensin receptor blockers (ARBs) should be discontinued when pregnancy is planned or recognized and replaced with pregnancy-compatible alternatives when necessary. Statins and most other lipid-lowering medications are also generally discontinued during pregnancy, although rare exceptions may be considered by the specialist team.
Because women with type 1 diabetes have an increased risk of preeclampsia, international guidelines recommend low-dose acetylsalicylic acid (aspirin), typically 100–150 mg daily starting between 12 and 16 weeks of gestation. The exact dose and timing should be discussed with the obstetric and diabetes care team.
Glucose targets during pregnancy are tighter than outside pregnancy.
According to the American Diabetes Association Standards of Care 2026, the following ranges are recommended for pregnant women with pre-existing type 1 diabetes:
Measurement | Recommended range |
Fasting glucose | 70–95 mg/dL (3.9–5.3 mmol/L) |
1 hour after a meal | 110–140 mg/dL (6.1–7.8 mmol/L) |
2 hours after a meal | 100–120 mg/dL (5.6–6.7 mmol/L) |
HbA1c | Ideally <6.0% (42 mmol/mol) if achievable without significant hypoglycemia |
Importantly, if an HbA1c below 6.0% can only be achieved at the cost of frequent or severe hypoglycemia, a less stringent target is appropriate. Depending on the individual situation, the HbA1c goal may be relaxed to approximately 7.0% (53 mmol/mol).
A very low HbA1c obtained at the expense of recurrent hypoglycemia is not a good treatment result.
HbA1c is also somewhat more difficult to interpret during pregnancy because red blood cell turnover increases, resulting in physiologically lower HbA1c levels. For day-to-day management, CGM data and glucose patterns therefore provide particularly valuable information.
Continuous glucose monitoring is specifically recommended for pregnant women with type 1 diabetes.
The pregnancy-specific CGM target range is narrower than outside pregnancy:
63–140 mg/dL (3.5–7.8 mmol/L).
Recommended CGM targets are:
CGM metric | Target |
Time in Range: 63–140 mg/dL (3.5–7.8 mmol/L) | >70% |
Time Above Range: >140 mg/dL | <25% |
Time Below Range: <63 mg/dL | <4% |
Time Below Range: <54 mg/dL | <1% |
These targets contain an important and reassuring message:
The goal is not 100% Time in Range.
A target of more than 70% Time in Range inherently acknowledges that some glucose readings will occur outside the pregnancy target range, even with very good diabetes management. At the same time, exposure to hypoglycemia should remain very low.
This does not mean that high glucose values should be ignored. It means that the pattern over hours, days, and weeks matters more than a single point on the CGM display.
A brief post-meal rise to 180 or 200 mg/dL (10.0–11.1 mmol/L) is above the recommended pregnancy range and ideally should be avoided. However, in the context of otherwise good glucose control, a single short-lived excursion does not mean that the baby has been harmed.
Calling such values completely “irrelevant” would be equally inappropriate.
The context matters.
A glucose level that briefly rises and then falls promptly is very different from glucose remaining elevated for several hours or from similar large excursions occurring every day.
The risk of diabetes-related pregnancy complications is primarily associated with the overall degree and duration of hyperglycemia and with recurrent glucose patterns, rather than with one isolated reading.
A practical way of interpreting glucose excursions is:
Situation | Interpretation |
Single brief rise followed by a falling glucose trend | Usually no reason for alarm; observe the pattern |
Similar rises repeatedly after a particular meal | Review insulin timing, carbohydrate amount and meal composition |
Increasing Time Above Range or persistent Time in Range below 70% | Discuss treatment adjustment with the diabetes team |
Glucose remains high for several hours or continues rising despite correction | Identify the cause; check insulin delivery and, if applicable, the pump/infusion set |
High glucose together with nausea, vomiting, illness or ketones | Requires prompt medical assessment |
Severe hypoglycemia or recurrent values below 54 mg/dL | Treatment should be reviewed promptly |
An individual glucose reading is therefore information—not a reason for fear.
Persistent hyperglycemia—and especially the presence of ketones—must be taken seriously.
During pregnancy, diabetic ketoacidosis (DKA) can develop at lower glucose concentrations than outside pregnancy and may occasionally occur even when glucose levels are below 200 mg/dL (11.1 mmol/L).
Women with type 1 diabetes should therefore have access to a blood ketone meter or another appropriate method of ketone testing, together with an individualized sick-day management plan.
Ketones should be checked particularly in the presence of:
Significantly elevated ketone levels, especially in combination with nausea, vomiting, abdominal symptoms or general illness, require rapid medical assessment.
This is especially important for insulin pump users. Pump therapy uses rapid-acting insulin without a long-acting subcutaneous insulin depot. If insulin delivery stops because of a blocked or dislodged infusion set, insulin deficiency—and therefore ketosis—can develop relatively quickly.
Several situations deserve particular attention during pregnancy:
And importantly: do not interpret every individual CGM reading as a judgment on the quality of the pregnancy. Trends and recurring patterns matter far more.
Hypoglycemia is particularly common during the first trimester. Insulin sensitivity often increases during early pregnancy, while nausea, vomiting and changes in appetite can make the effects of insulin more difficult to predict.
Severe hypoglycemia is primarily dangerous for the mother because it can cause:
Available evidence has not demonstrated an association between maternal hypoglycemia and congenital malformations, although the possible long-term consequences of repeated or severe episodes are not completely understood.
CGM systems with predictive alerts and AID systems can help reduce exposure to hypoglycemia.
An unexpectedly low CGM reading should also be interpreted in context. CGM measures glucose in the interstitial fluid rather than directly in the blood, and readings can lag slightly behind blood glucose changes.
In addition, pressure on the sensor during sleep can occasionally produce a falsely low reading—a so-called compression low.
If a low CGM value does not fit the symptoms or clinical situation, a finger-stick measurement may therefore be useful when practical. However, suspected true hypoglycemia should always be treated promptly rather than delaying treatment while waiting for confirmation.
Insulin requirements change substantially during pregnancy.
First trimester
Insulin sensitivity frequently increases and insulin requirements may decrease. Hypoglycemia is therefore more common during early pregnancy.
Second half of pregnancy
Placental hormones progressively increase insulin resistance. As pregnancy advances, insulin requirements often rise substantially.
During the third trimester, many women require approximately 1.5 to 2 times their pre-pregnancy insulin dose, although the degree of increase varies considerably between individuals.
Final weeks of pregnancy
Insulin requirements may plateau or sometimes decline slightly near the end of pregnancy.
A modest reduction in insulin requirements by itself does not prove placental insufficiency. However, a substantial or unexpected fall—particularly when accompanied by obstetric abnormalities or changes in fetal well-being—should be discussed promptly with the specialist obstetric and diabetes team.
Women with diabetic kidney disease, hypertension or significant vascular complications require particularly careful monitoring during pregnancy.
Maternal vascular disease can impair placental blood flow and may therefore reduce the delivery of oxygen and nutrients to the developing baby.
Pre-existing diabetic retinopathy may also progress during pregnancy, particularly when glucose control improves rapidly.
A retinal examination should therefore be performed before pregnancy or early in pregnancy. Women with established retinopathy usually require additional ophthalmological monitoring during pregnancy, often in each trimester.
Automated insulin delivery systems combine:
These systems represent one of the most important advances in the management of type 1 diabetes during pregnancy.
The ADA Standards of Care 2026 recommend AID systems with pregnancy-specific glucose targets for pregnant women with type 1 diabetes.
Other AID systems may also be considered in specialist care when their glucose targets and algorithm characteristics can be adapted appropriately to the much tighter glucose requirements of pregnancy.
Regulatory indications differ between systems and countries and are evolving rapidly.
CamAPS FX is specifically designed for use during pregnancy and allows pregnancy-appropriate glucose targets.
The MiniMed 780G has also been extensively studied during pregnancy, including in the CRISTAL randomized trial. Its regulatory pregnancy indication should be checked according to the respective country and current product labeling.
An important development occurred in June 2026: Tandem Diabetes Care received CE marking in Europe for the use of the t:slim X2 and Tandem Mobi insulin delivery systems with the new Control-IQ+ technology in women with type 1 diabetes during pregnancy.
The distinction between the older and newer algorithm is important:
System | Pregnancy indication |
t:slim X2 with the previous Control-IQ technology | No specific pregnancy indication |
t:slim X2 with Control-IQ+ | CE-marked in 2026 for use in type 1 diabetes during pregnancy |
Tandem Mobi with Control-IQ+ | Also CE-marked for use in type 1 diabetes during pregnancy |
Actual availability and compatible CGM combinations may differ between European countries.
Because algorithms differ in their target glucose settings, correction behavior and automated insulin delivery, the most appropriate system should be selected individually with an experienced diabetes-in-pregnancy team.
The benefits of pregnancy-specific AID were demonstrated particularly clearly in the AiDAPT trial.
Women using hybrid closed-loop therapy spent 68.2% of the day within the pregnancy target range, compared with 55.6% with standard insulin therapy. This corresponded to approximately 2.5 additional hours per day in the pregnancy glucose target range, with particularly favorable overnight control and without an increase in hypoglycemia.
The CRISTAL trial, which investigated the MiniMed 780G, did not show a statistically significant improvement in the primary outcome of overall pregnancy Time in Range, but demonstrated important benefits particularly overnight, together with less time below range and improved treatment satisfaction.
These studies illustrate another important point:
Even with highly advanced diabetes technology, many pregnant women do not consistently achieve more than 70% Time in Range—and virtually nobody achieves 100%.
Pregnancy glucose targets are demanding. Expecting absolute perfection is therefore neither realistic nor fair.
Experienced diabetes teams do not react to every isolated glucose reading. Instead, they work with the woman to identify patterns.
A substantial glucose rise after breakfast on three consecutive days provides much more useful information than a single reading of 190 mg/dL after an unusual meal.
Possible factors to review include:
CGM alarm limits should also be chosen carefully.
Too many alarms can lead to alarm fatigue, anxiety and eventually reduced attention to genuinely important warnings. At the same time, clinically important hypoglycemia and hyperglycemia alerts must remain effective.
The goal is therefore not maximum control every minute of every day.
The goal is to achieve as much time as possible within a safe glucose range while keeping both hypoglycemia and the psychological burden of diabetes management as low as possible.
A useful principle is:
Respond to patterns, not to every individual point.
A temporary glucose rise that subsequently returns toward the target range is something to observe—not something for which a woman should blame herself.
If the same rise repeatedly occurs after a particular meal, the diabetes team can adjust:
More urgent action is required when:
These situations warrant prompt assessment and, where appropriate, adjustment of therapy
Pregnancy should be managed jointly by a diabetes team and an obstetric team experienced in pregnancies complicated by type 1 diabetes.
CGM downloads, remote monitoring and telemedicine now allow many insulin adjustments to be made between scheduled appointments.
Monitoring typically includes:
Ultrasound examinations may be performed more frequently than in pregnancies without diabetes.
Delivery should ideally be planned in a hospital experienced in the management of diabetes during labor and with appropriate neonatal care available.
Women using insulin pumps or AID systems can often continue using their own system during labor and delivery if they are clinically stable, able to manage the device and the obstetric and diabetes teams agree that this is appropriate.
This approach should preferably be discussed before labor begins and documented in the birth plan.
Hospital protocols differ. Therefore, rather than waiting until labor, women who wish to continue self-management with their pump or AID system should discuss this with the diabetes and obstetric teams well in advance.
With an uncomplicated pregnancy, vaginal delivery is entirely possible. The timing and mode of delivery depend on the individual obstetric situation, fetal growth, maternal health and glucose control.
Once the placenta is delivered, the placental hormones responsible for pregnancy-induced insulin resistance disappear rapidly.
As a result, insulin requirements fall dramatically within hours after delivery.
Postpartum insulin doses should therefore be planned before delivery and usually need to be substantially reduced immediately afterward.
In one study of women with well-controlled type 1 diabetes, total daily insulin requirements shortly after delivery were approximately 34% lower than before pregnancy. Insulin requirements generally move back toward the pre-pregnancy level during the following weeks, although there is considerable individual variation.
However, insulin must never be discontinued completely in a woman with type 1 diabetes.
Basal insulin remains essential after delivery. Without it, insulin deficiency and diabetic ketoacidosis can develop.
Breastfeeding is recommended for women with type 1 diabetes.
Glucose levels may fall during or after breastfeeding, and the risk of hypoglycemia can be increased, particularly during the first weeks after delivery.
Several factors contribute:
Insulin doses should therefore be adjusted individually.
Keeping fast-acting carbohydrates readily available—particularly during nighttime breastfeeding—can be useful.
Good glucose control during pregnancy is important—but perfection is neither realistic nor necessary.
The realistic goal is therefore:
As much time as possible within the safe glucose range—with as little hypoglycemia and hyperglycemia as possible, without allowing pregnancy to become a constant struggle with every single sensor reading.
Good diabetes management during pregnancy means aiming for excellent overall control while recognizing that individual glucose fluctuations are inevitable—and that a successful pregnancy is not defined by a perfect CGM trace.